Dianthus Therapeutics (NASDAQ:DNTH) Price Target Cut to $36.00 by Analysts at Wedbush

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective cut by Wedbush from $38.00 to $36.00 in a research report released on Friday, Benzinga reports. They currently have an outperform rating on the stock.

A number of other analysts have also commented on the company. Lifesci Capital upgraded Dianthus Therapeutics to a strong-buy rating in a report on Tuesday, June 11th. Raymond James upped their price target on Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an outperform rating in a research report on Thursday, April 18th. HC Wainwright assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, May 16th. They issued a buy rating and a $40.00 price objective on the stock. Robert W. Baird started coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an outperform rating and a $58.00 target price for the company. Finally, Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They issued an overweight rating on the stock. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $44.71.

Dianthus Therapeutics Price Performance

DNTH traded up $0.76 during trading on Friday, reaching $27.50. The company had a trading volume of 145,393 shares, compared to its average volume of 194,359. The company has a market cap of $807.10 million, a P/E ratio of -4.72 and a beta of 1.89. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77. The business’s fifty day moving average price is $26.34 and its 200 day moving average price is $25.05.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.11). The company had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.48 million. As a group, sell-side analysts predict that Dianthus Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNTH. Tower Research Capital LLC TRC bought a new position in Dianthus Therapeutics during the 4th quarter worth $25,000. SG Americas Securities LLC bought a new position in shares of Dianthus Therapeutics in the second quarter worth $112,000. American Century Companies Inc. raised its stake in Dianthus Therapeutics by 38.6% in the second quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after purchasing an additional 8,473 shares in the last quarter. WINTON GROUP Ltd bought a new stake in Dianthus Therapeutics during the second quarter worth about $265,000. Finally, Virtu Financial LLC acquired a new stake in Dianthus Therapeutics during the first quarter worth about $390,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.